Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 2Suspended 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Neoplasms 1Neoplasm Metastasis 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
abarelix × Clear all
NCT00841113 2009-02-11

Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer

Speciality European Pharma Limited

Phase 3 Completed
177 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00100243 2006-09-19

Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

PRAECIS Pharmaceuticals Inc.

Phase 2 Completed
22 enrolled
Genitourinary

Prostatic Neoplasms

NCT00103623 2006-09-19

The Plenaxis® Experience Study

PRAECIS Pharmaceuticals Inc.

Phase 4 Suspended
2,000 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡